Results 21 to 30 of about 24,637 (218)

Expanding the role of insulin resistance to the earliest phases of cognitive decline: Preliminary evidence. [PDF]

Alzheimers Dement
Alzheimer's &Dementia, Volume 22, Issue 6, June 2026.
Mazzeo S, Frijo A, Corbari MV, Bortolin E, Bruschi G, Bombaci A, Pozzi FE, Astengo A, Magrì F, Pettinato A, Costa E, Filippi M, Salsone M.   +12 more
europepmc   +2 more sources

Pharmacogenomics of Type 2 Diabetes Mellitus; A Step Toward Personalized Medicine

NUST Journal of Natural Sciences, 2021
Type 2 diabetes is a complex multifactorial disease characterized by insufficient insulin secretion and insulin resistance. Global prevalence of diabetes is increasing day by day making diabetes a global epidemic.
Asima Zia, Attya Bhatti, Peter John, Aysha Kiani   +3 more
doaj   +1 more source

Safety and Effectiveness of Rosiglitazone in Type 2 Diabetes Patients with Nonalcoholic Fatty Liver Disease

Journal of the Formosan Medical Association, 2006
Nonalcoholic fatty liver disease (NAFLD) is a common chronic liver disease ranging in severity from steatosis to cirrhosis. Type 2 diabetes mellitus is a cause of primary NAFLD.
Chao-Hung Wang, Ching-Hsiang Leung, Sung-Chen Liu, Cheng-Ho Chung   +3 more
doaj   +1 more source

Review of the Case Reports on Metformin, Sulfonylurea, and Thiazolidinedione Therapies in Type 2 Diabetes Mellitus Patients

Medical Sciences, 2023
Type 2 diabetes mellitus (T2DM) is the world’s most common metabolic disease. The development of T2DM is mainly caused by a combination of two factors: the failure of insulin secretion by the pancreatic β-cells and the inability of insulin-sensitive ...
Elis Susilawati, Jutti Levita, Yasmiwar Susilawati, Sri Adi Sumiwi   +3 more
doaj   +1 more source

PPARgamma: A Potential Intrinsic and Extrinsic Molecular Target for Breast Cancer Therapy

Biomedicines, 2021
Over the last decades, the breast tumor microenvironment (TME) has been increasingly recognized as a key player in tumor development and progression and as a promising prognostic and therapeutic target for breast cancer patients.
Giuseppina Augimeri, Daniela Bonofiglio
doaj   +1 more source

Impact of Various Oral Hypoglycemic Agents on Hepatic Steatosis Reduction in MASLD and Type 2 Diabetes: Exploring the Bidirectional Relationship. A Narrative Review

Clinical Diabetology
OBJECTIVE: This review aims to explore the impact of various classes of oral hypoglycemic agents on hepatic steatosis reduction and liver functions in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) and type 2 diabetes (T2D)
Emilia Kowalczyk, Iwona Gorczyca-Głowacka, Gerard Stupecki, Agnieszka Ciba-Stemplewska, Magdalena Dolecka-Ślusarczyk, Przemysław Wolak   +5 more
doaj   +1 more source

Clinical effect of thiazolidinediones in subjects with disorders of carbohydrate metabolism in case of polymorphism rs1801282

Ожирение и метаболизм, 2020
BACKGROUND: The polymorphism rs1801282 (Pro12Ala) may be one of the reasons for the heterogeneous response of patients with carbohydrate metabolism disorders to thiazolidinedione therapy.
Tatyana V. Eremenko, Nikolay A. Matsievskiy, Natalya V. Vorokhobina, Irina Y. Matesius, Irina N. Abramashvili   +4 more
doaj   +1 more source

Comparison of the Effects of Metformin and Thiazolidinediones on Bone Metabolism: A Systematic Review and Meta-Analysis

Medicina, 2023
Objectives: Studies have shown that people with diabetes have a high risk of osteoporosis and fractures. The effect of diabetic medications on bone disease cannot be ignored.
Ru-Dong Chen, Cong-Wen Yang, Qing-Run Zhu, Yu Li, Hai-Feng Hu, Da-Chuan Wang, Shi-Jie Han   +6 more
doaj   +1 more source

Trends in the utilization, expenditure and costs of noninsulin glucose‐lowering drugs in the Medicaid population: Steady increases in glucagon‐like peptide‐1 receptor agonist and sodium–glucose transporter‐2 inhibitor use, prices and expenditure

British Journal of Clinical Pharmacology, EarlyView.
Aims This study aimed to analyse changes in the utilization, expenditure and average cost of noninsulin glucose‐lowering drugs (GLDs) between 2008 and 2023. Methods This was a retrospective observational study of 2008–2023 data from the National Medicaid State Drug Utilization database.
Rawan O. Almadfaa
wiley   +1 more source

Pharmacogenetics of Anti-Diabetes Drugs

Pharmaceuticals, 2010
A variety of treatment modalities exist for individuals with type 2 diabetes mellitus (T2D). In addition to dietary and physical activity interventions, T2D is also treated pharmacologically with nine major classes of approved drugs.
Johanna K. DiStefano, Richard M. Watanabe   +1 more
doaj   +1 more source